Core Insights - Apogee Therapeutics (NASDAQ:APGE) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a current price target of $95 set by Citi analyst Geoff Meacham, indicating a potential upside of over 37% [1] - RBC Capital analyst Brian Abrahams downgraded Apogee Therapeutics from Outperform to Sector Perform, while raising the price target from $70 to $83, suggesting nearly 20% upside [2] - The market reaction to the release of Sanofi's Phase 3 amlitelimab data is viewed as an overreaction, with Meacham asserting that it does not negatively impact the prospects for Apogee's APG279 candidate [1] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for treating inflammatory and immune diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis [4] - The company's pipeline includes several candidates at different clinical trial stages, such as APG777, APG279, APG990, APG333, and APG808 [4] Market Context - The segment in which Apogee operates is becoming increasingly competitive, with established players posing challenges despite the potential of its primary drug, zumilokibart, as a long-acting IL-13 treatment for atopic dermatitis [3] - The share price of Apogee has surged by 108% over the past year, which may limit the potential for further gains [3]

The iShares Morningstar Small-Cap ETF ((NYSEMKT:ISCB)) and Vanguard Small-Cap ETF ((NYSEMKT:VB)) both offer broad U.S. small-cap exposure, but ISCB delivered stronger recent returns and holds more names, while VB is far larger, more liquid, and a touch less volatile. Both the iShares Morningstar Small-Cap ETF and Vanguard Small-Cap ETF aim to track the U.S. small-cap segment, providing investors with diversified access to hundreds of smaller companies. This comparison looks at how ISCB’s portfolio and ris ...

On February 12, 2026, Barington Companies Management disclosed a new position in Americold Realty Trust (NYSE:COLD), acquiring 300,000 shares in a transaction estimated at $3.86 million based on quarterly average pricing. What happened According to a SEC filing dated February 12, 2026, Barington Companies Management reported establishing a new position in Americold Realty Trust by purchasing 300,000 shares during the fourth quarter. The quarter-end value of the stake stood at $3.86 million, reflecting th ...

Turning 65 is a major milestone for one big reason -- it's when you're eligible for health coverage under Medicare. But if you're still working at age 65, Medicare coverage may not be necessary. If your job provides you with health insurance, you may still be able to sign up for Medicare and use it as secondary insurance. But that also may not be necessary. And since there's a cost to Medicare Part B, if you're still working at 65, you may decide to delay your enrollment. Will AI create the world's first ...

Amazon (NASDAQ: AMZN) is a well-known tech behemoth. Plenty of people use its commerce platform, and its name has become synonmous wth online shopping. Amazon is also competing in the artificial intelligence (AI) space, with its Amazon Web Services (AWS) cloud computing division. Despite operating in those lucrative areas, Amazon's growth rate has slowed a bit, and its stock price is underperforming. This opens it up to be passed by others who are operating at a high level. Two stocks that are crushing it ...

Addressing Apollo’s “Private Credit: Fact or Fiction?” white paper, Zelter said “private credit” is often narrowly defined by direct lending, but Apollo views it as much broader—encompassing assets that historically sat on bank balance sheets or were not part of liquid markets. He traced the rise of sponsor-backed direct lending as a third leg of non-investment-grade financing alongside high-yield bonds and leveraged loans, describing its growth from “zero to $2 trillion.”Using a golf analogy, Zelter said t ...

When one partner has more than $100,000 saved and zero debt, while the other is tens of thousands in debt, tension is almost inevitable. Add in expensive vacations and one person quietly footing every bill, and even a strong relationship can start to feel uneven. That was the dilemma shared by a young man on “The Ramsey Show” recently. He earns $135,000 a year, maxes out his 401(k) and has built six figures in savings. His girlfriend earns about $50,000 and carries between $70,000 and $80,000 in debt. He ...

Chinese carmaker Great Wall Motor (GWM) is preparing a European relaunch centred on hybrid and combustion vehicles and a regional plant by 2030. The company intends to build a European factory with annual capacity of 300,000 vehicles by the end of the decade as part of a broader goal to double overseas sales to one million units. Parker Shi, president of GWM International, said in an interview reported by Reuters that Europe is critical to achieving the company’s 2030 target. GWM’s renewed effort follo ...

The U.S. stock market will remain closed for trading on Feb. 16 in observance of Presidents' Day. Both exchanges, the New York Stock Exchange and the Nasdaq, will remain suspended on the day. Celebrated on the third Monday of February, it is a holiday in the United States and is an occasion to honor the legacy of the presidents of the country. The trading activity will resume on Feb. 17. Related: Bitget CEO who predicted $200K Bitcoin says it’s a ‘good time to buy’ However, trading on the cryptocurrenc ...

Core Viewpoint - Tesla is gaining attention as a potential investment in the AI sector due to its transition towards autonomous vehicles and humanoid robots, despite facing challenges such as declining sales and rising expenses [1][5]. Group 1: Analyst Optimism - Some analysts are becoming increasingly bullish on Tesla, particularly due to its self-driving car ambitions and the potential for significant revenue from robotaxi services, projected to reach $250 billion by 2035 [2][3]. - Wolfe Research analyst Emmanuel Rosner highlighted that 2026 will be a "catalyst-rich year" for Tesla, with at least 17 analysts currently holding a buy rating on the stock [2][3]. Group 2: Financial Performance - Tesla's gross margin improved to 20.1% in the fourth quarter, the highest in two years, and the company ended 2025 with $44 billion in cash and investments, a 20% increase from 2024 [3]. - However, Tesla's revenue fell by 3% in 2025, marking its first annual decline, while earnings dropped 47% to $1.08 per share, with vehicle revenue decreasing by 10% to $65.5 billion due to slowing consumer demand for EVs [6]. Group 3: Market Potential - The autonomous vehicle market could be valued at $1.4 trillion by 2040, and humanoid robotics may reach an estimated $5 trillion by 2050, indicating significant growth potential for Tesla if it can overcome current challenges [4].